Whole Animal Assay for Angiogenesis Inhibition

描述(由申请人提供)：目前有强烈的兴趣 天然蛋白质，如凝血酶原蛋白、血小板因子-4、血管抑素和 内皮抑素，作为癌症和其他疾病的治疗药物，因为缺乏 副作用和耐药性的发展。第一阶段研究证明 斑马鱼是筛选蛋白质和 具有抗血管生成作用的化合物。一种酶分析方法是 成功地开发了量化血管生长的方法，并获得了明确的剂量响应 观察了几种药物。在第二阶段的研究中，将使用酶分析 以确定蛋白质药物检测的最佳检测条件，然后使用 筛选治疗药物候选药物。自综合性商品药以来 筛查项目依赖于一些验证性的测试来评估药物 特异性，第二阶段研究还将开发一系列血管特异性 以单抗(MAb)为基础的检测来补充酶检测。第二阶段 研究还将使用基于血管特异性单抗的标记来阐明 血管生成的机制。 建议的商业应用：不可用

DESCRIPTION (provided by applicant): Currently there is strong interest in natural proteins, such as thrombospondins, Platelet factor-4, angiostatin and endostatin, as therapeutics for cancer and other diseases, because of the lack of side effects and drug resistance development. Phase I studies demonstrated that the zebrafish is a viable whole animal model for screening proteins and chemical compounds for anti-angiogenic effects. An enzyme assay was successfully developed to quantify vessel growth and a clear dose response was observed for several drugs. In Phase II research, the enzyme assay will be used to determine optimum assay conditions for protein drug testing, and then used to screen therapeutic drug candidates. Since comprehensive commercial drug screening programs rely on a number of confirmatory assays to assess drug specificity, Phase II research will also develop a family of vessel specific monoclonal antibody (mAb) based assays to complement the enzyme assay. Phase II research will also use the vessel specific mAb based markers to elucidate the mechanisms of angiogenesis. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE